OncoMatch/Clinical Trials/NCT06418477
Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD
Is NCT06418477 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Dara-CyBorD for monoclonal gammopathy of renal significance.
Treatment: Dara-CyBorD — This is an open-label, multicenter, Phase 2 study in subjects with newly diagnosed monoclonal immunoglobulin deposition disease treated with daratumumab, bortezomib, cyclophosphamide, and dexamethasone.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: anti-plasma cell treatment
Exception: ≤160 mg dexamethasone (or equivalent corticosteroid)
Prior therapy for MIDD, with the exception of equal or less than 160 mg dexamethasone (or equivalent corticosteroid)
Lab requirements
Blood counts
Neu≥ 1.0*10^9/L, HGB ≥70g/L, PLT ≥ 50*10^9/L
Liver function
Total bilirubin (TBil) ≤3×upper limit of normal (ULN); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3.0×ULN
Neu≥ 1.0*10^9/L, HGB ≥70g/L, PLT ≥ 50*10^9/L. Total bilirubin (TBil) ≤3×upper limit of normal (ULN); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3.0×ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06418477 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify